New pill shows promise for rare lung cancer mutations

NCT ID NCT06010329

Recruiting now Disease control Sponsor: Teligene US Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing an oral drug called sutetinib maleate in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors and control the disease. About 66 adults will take the drug and be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sutetinib maleate (a targeted cancer drug taken orally)
What this could lead to: If successful, this could provide a new treatment option for people with non-small cell lung cancer that has uncommon EGFR mutations, potentially shrinking tumors and delaying progression.
What could go wrong: This is an early-phase (Phase 2) trial with only 66 participants, so results may not apply to everyone. The drug may cause side effects and may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Mission Cancer + Blood - Mission Cancer Foundation
RECRUITING

Des Moines, Iowa, 50309, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Northwell Health
ACTIVE_NOT_RECRUITING

New Hyde Park, New York, 11042, United States
Norton Cancer Institute - Downtown
WITHDRAWN

Louisville, Kentucky, 40202, United States
Oncology Physicians Network Healthcare
WITHDRAWN

Glendale, California, 91203, United States
Perlmutter Cancer Center - 34th Street
RECRUITING

New York, New York, 10016, United States
University Cancer & Blood Center (UCBC) - Athens
RECRUITING

Athens, Georgia, 30607, United States
University of California San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.